139 related articles for article (PubMed ID: 23862718)
1. Cereblon expression in multiple myeloma: not ready for prime time.
Lodé L; Amiot M; Maiga S; Touzeau C; Menard A; Magrangeas F; Minvielle S; Pellat-Deceunynck C; Bene MC; Moreau P
Br J Haematol; 2013 Oct; 163(2):282-4. PubMed ID: 23862718
[No Abstract] [Full Text] [Related]
2. Cereblon expression in multiple myeloma: not ready for prime time - response to Lodé et al.
Zojer N; Heintel D; Palumbo A; Ludwig H
Br J Haematol; 2013 Oct; 163(2):285-6. PubMed ID: 23869521
[No Abstract] [Full Text] [Related]
3. Thalidomide-based induction regimens are as effective as bortezomib-based regimens in elderly patients with multiple myeloma with cereblon expression.
Jung SH; Choi HJ; Shin MG; Lee SS; Hwang EC; Jung TY; Cho MS; Yang DH; Ahn JS; Kim YK; Kim HJ; Lee JJ
Ann Hematol; 2016 Oct; 95(10):1645-51. PubMed ID: 27365142
[TBL] [Abstract][Full Text] [Related]
4. Do baseline Cereblon gene expression and IL-6 receptor expression determine the response to thalidomide-dexamethasone treatment in multiple myeloma patients?
Bedewy AM; El-Maghraby SM
Eur J Haematol; 2014 Jan; 92(1):13-8. PubMed ID: 24118365
[TBL] [Abstract][Full Text] [Related]
5. Pan-PIM kinase inhibitors enhance Lenalidomide's anti-myeloma activity via cereblon-IKZF1/3 cascade.
Zheng J; Sha Y; Roof L; Foreman O; Lazarchick J; Venkta JK; Kozlowski C; Gasparetto C; Chao N; Ebens A; Hu J; Kang Y
Cancer Lett; 2019 Jan; 440-441():1-10. PubMed ID: 30312729
[TBL] [Abstract][Full Text] [Related]
6. Chemoprevention for smoldering multiple myeloma: not ready for prime time.
Gertz MA
Leuk Lymphoma; 2013 Oct; 54(10):2331-2. PubMed ID: 23540344
[No Abstract] [Full Text] [Related]
7. IMiDs: Not for the CRBN weak.
Pearse RN
Leuk Res; 2014 Jan; 38(1):21-2. PubMed ID: 24239176
[No Abstract] [Full Text] [Related]
8. [Cereblon - a new target of therapy in the treatment of multiple myeloma].
Staňková M; Bešše L; Sedlaříková L; Vrábel D; Hájek R; Sevčíková S
Klin Onkol; 2014; 27(5):326-30. PubMed ID: 25312709
[TBL] [Abstract][Full Text] [Related]
9. [Thalidomide, cereblon and multiple myeloma].
Ogura T
Nihon Rinsho; 2015 Jan; 73(1):149-55. PubMed ID: 25626321
[TBL] [Abstract][Full Text] [Related]
10. Cereblon binding molecules in multiple myeloma.
Kortüm KM; Zhu YX; Shi CX; Jedlowski P; Stewart AK
Blood Rev; 2015 Sep; 29(5):329-34. PubMed ID: 25843596
[TBL] [Abstract][Full Text] [Related]
11. IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM).
Krönke J; Kuchenbauer F; Kull M; Teleanu V; Bullinger L; Bunjes D; Greiner A; Kolmus S; Köpff S; Schreder M; Mügge LO; Straka C; Engelhardt M; Döhner H; Einsele H; Bassermann F; Bargou R; Knop S; Langer C
Leukemia; 2017 Jun; 31(6):1363-1367. PubMed ID: 28017969
[TBL] [Abstract][Full Text] [Related]
12. [Clear cell myeloma: report of a case].
Xu H; Li J; Yang S
Zhonghua Bing Li Xue Za Zhi; 2014 Mar; 43(3):196-7. PubMed ID: 24842022
[No Abstract] [Full Text] [Related]
13. Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN.
Bjorklund CC; Kang J; Amatangelo M; Polonskaia A; Katz M; Chiu H; Couto S; Wang M; Ren Y; Ortiz M; Towfic F; Flynt JE; Pierceall W; Thakurta A
Leukemia; 2020 Apr; 34(4):1197-1201. PubMed ID: 31719682
[No Abstract] [Full Text] [Related]
14. Cereblon and IRF4 Variants Affect Risk and Response to Treatment in Multiple Myeloma.
Butrym A; Łacina P; Rybka J; Chaszczewska-Markowska M; Mazur G; Bogunia-Kubik K
Arch Immunol Ther Exp (Warsz); 2016 Dec; 64(Suppl 1):151-156. PubMed ID: 28083618
[TBL] [Abstract][Full Text] [Related]
15. A Dual Color Immunohistochemistry Assay for Measurement of Cereblon in Multiple Myeloma Patient Samples.
Ren Y; Wang M; Couto S; Hansel DE; Miller K; Lopez-Girona A; Bjorklund CC; Gandhi AK; Thakurta A; Chopra R; Breider M
Appl Immunohistochem Mol Morphol; 2016; 24(10):695-702. PubMed ID: 26186254
[TBL] [Abstract][Full Text] [Related]
16. Comparative proteomic profiling of refractory/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy.
Dytfeld D; Luczak M; Wrobel T; Usnarska-Zubkiewicz L; Brzezniakiewicz K; Jamroziak K; Giannopoulos K; Przybylowicz-Chalecka A; Ratajczak B; Czerwinska-Rybak J; Nowicki A; Joks M; Czechowska E; Zawartko M; Szczepaniak T; Grzasko N; Morawska M; Bochenek M; Kubicki T; Morawska M; Tusznio K; Jakubowiak A; Komarnicki MA
Oncotarget; 2016 Aug; 7(35):56726-56736. PubMed ID: 27527861
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors in multiple myeloma: the M.D. Anderson experience.
Barlogie B; Alexanian R
Eur J Haematol Suppl; 1989; 51():84-7. PubMed ID: 2627993
[No Abstract] [Full Text] [Related]
18. Resistant multiple myeloma treated with mitozantrone in combination with vincristine and dexamethasone (MOD).
Phillips JK
Eur J Haematol; 1989 Jan; 42(1):109-10. PubMed ID: 2914592
[No Abstract] [Full Text] [Related]
19. Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent manner.
Dimopoulos K; Søgaard Helbo A; Fibiger Munch-Petersen H; Sjö L; Christensen J; Sommer Kristensen L; Asmar F; Hermansen NEU; O'Connel C; Gimsing P; Liang G; Grønbaek K
Mol Oncol; 2018 Feb; 12(2):180-195. PubMed ID: 29130642
[TBL] [Abstract][Full Text] [Related]
20. Loss of CD38 Expression in Relapsed Refractory Multiple Myeloma.
Ise M; Matsubayashi K; Tsujimura H; Kumagai K
Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):e59-64. PubMed ID: 26997107
[No Abstract] [Full Text] [Related]
[Next] [New Search]
